A landmark French trial will seek to settle one of the country’s biggest pharmaceutical scandals, probing whether the company behind a weight-loss drug believed to have triggered killer side effects covered up the risks.

Novartis announced results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto in patients with heart failure with reduced ejection fraction (HFrEF).

The U.S. Food and Drug Administration granted fast track status for the development of AstraZeneca’s diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.

AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.

Novartis’ heart failure drug Entresto failed a clinical trial in a new use, the Swiss drugmaker said, calling into question billions of dollars in potential revenue and taking the shine off one of the company’s largest growth prospects.

In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

Early detection of cardiovascular disease is becoming possible due to research from Giovanna Guidoboni, Marjorie Skubic and a team at the University of Missouri.

More U.S. adults are dying from heart failure today than a decade ago, and the sharpest rise in mortality is happening among middle-aged and younger adults, a new study suggests.

Asklepios BioPharmaceutical (AskBio) secured a $235 million investment from Vida Ventures and TPG Capital.

The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.